Chemours (CC) reported $1.5 billion in revenue for the quarter ended September 2025, representing a year-over-year decline of 0.4%. EPS of $0.20 for the same period compares to $0.40 a year ago.
The reported revenue represents a surprise of +0.19% over the Zacks Consensus Estimate of $1.49 billion. With the consensus EPS estimate being $0.24, the EPS surprise was -16.67%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Chemours performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Other Segment: $12 million compared to the $14.67 million average estimate based on four analysts. The reported number represents a change of -14.3% year over year.
- Revenues- Titanium Technologies: $612 million versus the four-analyst average estimate of $634.1 million. The reported number represents a year-over-year change of -9.9%.
- Revenues- Advanced Performance Materials: $311 million versus the four-analyst average estimate of $297 million. The reported number represents a year-over-year change of -10.6%.
- Revenues- Thermal & Specialized Solutions: $560 million compared to the $563.96 million average estimate based on four analysts. The reported number represents a change of +21.7% year over year.
- Adjusted EBITDA- Titanium Technologies: $25 million versus the four-analyst average estimate of $39.7 million.
- Adjusted EBITDA- Corporate and Other: $-38 million compared to the $-50.99 million average estimate based on four analysts.
- Adjusted EBITDA- Other Segment: $2 million compared to the $2.31 million average estimate based on four analysts.
- Adjusted EBITDA- Advanced Performance Materials: $14 million compared to the $14.9 million average estimate based on four analysts.
- Adjusted EBITDA- Thermal & Specialized Solutions: $194 million versus the four-analyst average estimate of $179.85 million.
View all Key Company Metrics for Chemours here>>>
Shares of Chemours have returned -19.9% over the past month versus the Zacks S&P 500 composite's +1.3% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The Chemours Company (CC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
